Status:

COMPLETED

Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients

Lead Sponsor:

VA Office of Research and Development

Collaborating Sponsors:

Baylor College of Medicine

Conditions:

COVID 19

Rehabilitation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Background: Conventional face-to-face in-hospital mobility program (MP) is challenging for COVID-19 patients because of its associated risk of infection to hospital staff, staffing shortages as well a...

Detailed Description

KEY RESEARCH AIMS: Aim 1: To examine feasibility of Tele-exergame. The investigators will evaluate feasibility by documenting missing exercise sessions, exercise dropout, and acceptability questionna...

Eligibility Criteria

Inclusion

  • Participants: Men or women Veterans with COVID-19 or PUI or hospitalized patients with duration of admission anticipated to be greater than 72 hours admitted to MEDVAMC.
  • Length of stay: Anticipated length of stay at least 3 days.
  • Ambulatory. Self-report of being ambulatory with or without an assistive device in the 2 weeks before admission.

Exclusion

  • ICU admission: The investigators will exclude those admitted to ICU at any point in their hospital stay.
  • Admission of observation only: These patients will be excluded as length of stay is usually anticipated to be less than 3 days
  • Median life expectancy: Those with imminently terminal (death expected in the next 30 days) will be excluded.
  • Cognitive impairment: The investigators will exclude those with delirium, dementia, or severe cognitive impairment
  • Medical condition: The investigators will exclude those who have any medical diagnosis deemed by the primary physician to be a contraindication to ambulation (i.e.: unstable from pulmonary embolus, unstable angina, severe hemodynamic instability etc.)
  • Foot problem: The investigators will exclude those who have active foot ulcer or infection or major lower extremities amputation.
  • Vision or hearing problems: The investigators will exclude those with hearing or visual problems that cannot be corrected with medical devices (glasses or hearing aids). Hearing or visual problems can limit their ability to interact with the exergame platform.
  • lack of capacity to consent, and inability or unwillingness to participate regularly in the exercise program;
  • unable to communicate in English or Spanish, or unlikely to fully comply with the follow-up protocol (e.g., lack of caregiver support to safely perform exercise tasks at home or complete the questionnaires).
  • Clarifying exclusion criteria
  • Ongoing treatment: The investigators will NOT exclude those who are participating in standard of care physical therapy program (Receipt of Physical Therapy (PT), Occupational Therapy (OT), Speech Therapy (ST), Mental Health (MH), and Social Work (SW) Services). However, the investigators will document these services and will control for it. However, those who are receiving non- standard of care exercise therapy (e.g. other exercise research study) or receiving active intensive or induction therapy for cancer (e.g. undergoing active initial chemotherapy or radiotherapy).
  • Others: The investigators will NOT exclude but will document common comorbidities such as pneumonia, heart failure, and chronic obstructive pulmonary disease exacerbations. Pulmonary embolism or acute coronary syndrome maybe included if there is no contraindications like severe hemodynamic instability or active angina.

Key Trial Info

Start Date :

July 5 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2023

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT04743401

Start Date

July 5 2021

End Date

December 31 2023

Last Update

January 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Michael E. DeBakey VA Medical Center, Houston, TX

Houston, Texas, United States, 77030-4211